Synlogic⢠is pioneering the development of a novel class of living Synthetic Biotic⢠medicines based on its proprietary drug discovery and development platform. Synlogicâs initial pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Phenylketonuria (PKU). In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders, and cancer. Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit synlogictx.com.
Source
